GLX Analytix is a biotechnology company dedicated to advancing the diagnosis and management of neurological diseases. Leveraging cutting-edge technology, GLX Analytix specializes in developing innovative diagnostic tools based on the analysis of biomarkers from the blood vessel wall, called the endothelial glycocalyx (GLX). Through its GLX Signature Platform, the company aims to provide precise and actionable insights, enabling earlier and more accurate diagnosis, improved patient care, and the potential for personalized treatment strategies. GLX Analytix is at the forefront of transforming how complex neurological conditions are detected and managed, offering hope for better outcomes in patient care.